Brief: Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302
17/12/2025 12:57
Dec 17 (Reuters) - Soligenix Inc SNGX.O: SOLIGENIX ANNOUNCES TOP-LINE RESULTS OF THE PHASE 2A STUDY OF SGX302 (SYNTHETIC HYPERICIN) IN PATIENTS WITH MILD-TO-MODERATE PSORIASIS SOLIGENIX INC - OPTIMIZED GEL FORMULATION SHOWS SUCCESS IN THIRD COHORT SOLIGENIX INC - SGX302 GEL THERAPY WELL TOLERATED WITH NO ADVERSE EVENTS SOLIGENIX INC - STUDY CONFIRMS SGX302 IMPROVES PSORIASIS LESIONS Source text: ID:nPn6rz1jda Further company coverage: SNGX.O ((Reuters.Briefs@thomsonreuters.com;))